A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden

References

• Hamel E. Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Therapeut 1992;55:31–51.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Therapeut 2005;4:1086–95.
   PubMed Web of Science ®Google Scholar
• Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013–21.
   PubMed Web of Science ®Google Scholar
• Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207–12.
   PubMed Web of Science ®Google Scholar
• Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15:4213–9.
   PubMed Web of Science ®Google Scholar
• Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922–8.
   PubMed Web of Science ®Google Scholar
• Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954–61.
   PubMed Web of Science ®Google Scholar
• Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012;23:1441–8.
   PubMed Web of Science ®Google Scholar
• McIntyre K, O’Shaughnessy J, Schwartzberg L, Gluck S, Berrak E, Song JX, et al. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat 2014;146:321–8.
   PubMed Web of Science ®Google Scholar
• Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 2011;377:914–23.
   PubMed Web of Science ®Google Scholar
• Halaven: EPAR – Product Information European Medicines Agency 2014 [updated 2014 Feb 7, 23/03/2014]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002084/WC500105112.pdf. (cited 2014 March 23).
   Google Scholar
• Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Wanders J, et al. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. [S6-6] Cancer Res2012;72(24 Suppl).Abstract.
   Google Scholar
• Ramaswami R, O’Cathail SM, Brindley JH, Silcocks P, Mahmoud S, Palmieri C. Activity of eribulin mesylate in heavilypretreated breast cancer granted accessvia the Cancer Drugs Fund. Future Oncol 2014;10:363–76.
   PubMed Web of Science ®Google Scholar
• Hattori M,Fujita T,Sawaki M,Kondo N,Horio A,Ushio A, et al.[Clinical efficacy and safety assessment of eribulin monotherapy in patients with metastatic breast cancer – a single-institute experience]. Gan To Kagaku Ryoho 2013; 40:737–41.
   PubMedGoogle Scholar
• Poletti P, Ghilardi V, Livraghi L, Milesi L, Rota Caremoli E, Tondini C. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: Current practice in an Italian community hospital. Future Oncol 2014;10:233–9.
   PubMed Web of Science ®Google Scholar
• Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, et al. Eribulin mesylate in pretreated breast cancer patients: A multicenter retrospective observational study. J Cancer 2014;5:320–7.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). National Cancer Institute; 2009 [14 March 2014]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. (cited 2014 March 14).
   Google Scholar
• Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst 2014;106:dju002.
   PubMed Web of Science ®Google Scholar